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Background
This study aims to detect Nevirapine (NVP) side effects
among patients started with lead in dose at initiation of
Anti Retroviral Therapy (ART) with CD4 count >250
cells/mm
3 in female and CD4 count >400 cells/mm
3 in
male.
Methods
Close monitoring was conducted for the detection of
NVP based side effects among ART - naïve patients
initiated on CD4 count >250 cells/mm
3 among women
and CD4 count > 400 cells/mm
3 are the study target at
Centre of Excellence (CoE), ART Centre, B. J. Medical
College, Civil Hospital, Ahmedabad, Gujarat, India.
Results
Total 5060 patients were initiated ART during the per-
iod of may 2005 to may 2009 at the institute. Among
this 3647 (72%) were initiated with NVP lead in dose as
per the Indian National ART Guidelines, Table 1.
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Table 1
Parameter Outcome
NVP lead in dose initiated patients 3647 (n)
Male 2408(66.02%)
Female 1239(33.97%)
Male with CD4 >400 cells/mm
3 and initiated NVP lead in dose (n = 2408) 47(1.95%)
Female with CD4 >250 cells/mm
3 and initiated NVP lead in dose (n = 1239) 112(9.03%)
NVP induced Rash Male (n = 47) 0
Female (n = 112) 5(4.46%)
NVP induced Hepatitis Male (n = 47) 1(2.12%)
Female (n = 112) 0
Male with CD4 <400 cells/mm
3 and initiated NVP lead in dose (n = 2408) 1629(67.64%)
Female with CD4 <250 cells/mm
3 and initiated NVP lead in dose (n = 1239) 838(67.63%)
NVP induced Rash Male (n = 1629) 19(1.16%)
Female (n = 838) 15(1.78%)
NVP induced Hepatitis Male (n = 1629) 5(0.30%)
Female (n = 838) 2(0.23%)
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Skin Rash was recovered on substituting with another
NNRTI- Efavirenz (EFV) and the treatment was well tol-
erated. Hepatitis was managed with substitution to EFV
and close follow-up on ALT and AST. Though western
literature has a black box warning for use of NVP, this
data shows if closely monitored it could be given at
resources limited settings with CD4 counts >250 cells/
mm
3 in females and >400 cells/mm
3 males. Nevirapine
is cost effective molecule compared to Efavirenz and
when given in such conditions of higher CD4 need close
follow up.
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